Cipla Limited announced that a routine current Good Manufacturing Practices (cGMP) inspection conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of its wholly owned subsidiary, InvaGenPharmaceuticals Inc., has concluded with zero Form 483 observations.
The regulatory audit was carried out from October 19, 2026, to October 22, 2026 (ET), at InvaGen’s manufacturing facility located in Hauppauge, Long Island, New York, USA. The clean outcome completed without any procedural or quality-related observations reaffirms the facility’s stringent adherence to global regulatory benchmarks and high-quality pharmaceutical manufacturing standards.
InvaGen Pharmaceuticals represents a core manufacturing asset in Cipla’s North American footprint, focusing on the development, manufacturing, and commercial supply of quality generic prescription formulations for the U.S. healthcare system. The successful conclusion of this routine cGMP review ensures continued, uninterrupted supply across Cipla’s existing commercial product lines while establishing robust operational support for upcoming abbreviated new drug application (ANDA) filings and product launches in the U.S. market.
In a formal regulatory disclosure submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla confirmed that the audit concluded without any Form 483 notices issued.
Cipla remains committed to maintaining best-in-class compliance protocols, operational transparency, and rigorous quality assurance systems across all domestic and international manufacturing sites to ensure patient safety and reliable global access to essential medicines.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
